InMed Pharmaceuticals

NASDAQ said InMed Pharmaceuticals has met the listing requirement after the closing price of its common stock was at or above $1.00 for ten consecutive trading days from May 19 through last Monday. The exchange has closed the matter; the stock currently trades at $1.56 and, despite a 50% year-to-date increase, remains well below the 52-week high of $5.50. InMed has a market capitalization of $6.96 million and is developing small-molecule drug candidates targeting CB1/CB2 receptors with programs for Alzheimer’s, eye diseases and dermatology. » Altro su de.investing.com

InMed Pharmaceuticals has filed a prospectus supplement and the related prospectus with the U.S. securities regulator SEC for the sale of common shares under an existing at-the-market agreement with H.C. Wainwright & Co. The filing relies on the S-3 shelf registration that the SEC declared effective on March 30, 2026. The supplement includes a legal opinion from Norton Rose Fulbright Canada LLP on the validity of the offered securities. » Altro su de.investing.com

InMed Pharmaceuticals received a notice from Nasdaq because the stock’s closing price was below $1.00 for 30 consecutive trading days between Feb. 11 and Mar. 26, 2026. The shares currently trade at $0.66 with a market capitalization of $2.59 million; InMed has 180 calendar days to cure the deficiency by achieving a closing price of at least $1.00 for ten consecutive trading days. If the company does not comply, a one-time extension is possible; otherwise delisting is threatened, with a possible appeal to the Nasdaq Hearings Panel. InMed is evaluating options such as a reverse stock split and will monitor the share price. » Altro su de.investing.com